Kikuchi T, Watanabe A. Baloxavir heralds a new era in influenza virus biology. Respir Investig. 2018 Nov 2
Baloxavir marboxil is an orally available prodrug of baloxavir acid. Japan was the first country to approve baloxavir marboxil as a treatment for influenza. The antiviral mechanism of action of baloxavir is unique; the drug blocks initiation of viral mRNA synthesis, thus preventing proliferation of the influenza virus. A single oral dose of baloxavir is usually well tolerated; it hastens alleviation of influenza symptoms and shortens the duration of viral shedding. However, novel influenza variants exhibiting over 10-fold reductions in baloxavir susceptibility emerged in baloxavir-treated patients. Although further clinical investigation is required to explore this issue, baloxavir may revolutionize our understanding of influenza virus biology.
See Also:
Latest articles in those days:
- Evolutionary Events Promoted Polymerase Activity of H13N8 Avian Influenza Virus 17 hours ago
- Cross-Species Transmission Potential of H4 Avian Influenza Viruses in China: Epidemiological and Evolutionary Study 17 hours ago
- Wild Bird-Origin H6N2 Influenza Virus Acquires Enhanced Pathogenicity after Single Passage in Mice 17 hours ago
- Genetics of H5N1 and H5N8 High-Pathogenicity Avian Influenza Viruses Isolated in Japan in Winter 2021-2022 17 hours ago
- Avian H6 Influenza Viruses in Vietnamese Live Bird Markets during 2018-2021 17 hours ago
[Go Top] [Close Window]